Vice President
Regeneron Genetics Center
Dr. Shuldiner is vice president at the Regeneron Genetics Center. The RGC has now sequenced DNA from more than 2 million individuals to identify novel variants in genes that provide new insights into human health and disease and facilitate drug development. He is also the John Whitehurst endowed Professor of Medicine (part-time) at the University of Maryland School of Medicine where he directs the Program for Personalized and Genomic Medicine, a program that focuses on implementing genomics into clinical practice. A leading national expert and researcher in precision medicine, Dr. Shuldiner focuses on the genetics of age-related diseases, including of type 2 diabetes, obesity, osteoporosis, and cardiovascular disease. He has published more than 500 original articles and serves on several steering and advisory committees related to his expertise in complex disease genetics and the translation of genetic discoveries to the clinical setting. He is best known for his studies involving Old Order Amish, a homogeneous population ideal for genetic studies. His group reported the first null mutation in the APOC3 gene and its association with low blood triglyceride levels and cardioprotection, which validates APOC3 as a target for treatment of hypertriglyceridemia and cardiovascular disease. Using genome-wide approaches, his group identified a common variant in CYP2C19 that reduces the benefit of clopidogrel. These findings and those of others have led the American Heart Association to recommend genetic testing to patients receiving anti-platelet therapy for more effective individualized therapy.
Thursday, May 29, 2025
11:00 AM - 12:00 PM East Coast USA Time